Land: Kanada
Tungumál: enska
Heimild: Health Canada
ENTACAPONE; CARBIDOPA; LEVODOPA
STRIDES PHARMA CANADA INC
N04BA03
LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR
200MG; 37.5MG; 150MG
TABLET
ENTACAPONE 200MG; CARBIDOPA 37.5MG; LEVODOPA 150MG
ORAL
100
Prescription
CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITORS
Active ingredient group (AIG) number: 0352427003; AHFS:
APPROVED
2021-07-07
1 PRODUCT MONOGRAPH Pr Levodopa, Carbidopa and Entacapone Tablets Tablets: 50 mg / 12.5 mg / 200 mg and 150 mg / 37.5 mg / 200 mg (levodopa / carbidopa / entacapone) Anti-Parkinsonian Dopaminergic Agent Strides Pharma Canada Inc. 1565, Boul. Lionel-Boulet Varennes, Quebec Canada, J3X 1P7 DATE OF PREPARATION: July 6, 2021 SUBMISSION CONTROL NO.: 220776 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.............................................................3 SUMMARY PRODUCT INFORMATION..............................................................................3 INDICATIONS AND CLINICAL USE ....................................................................................3 CONTRAINDICATIONS........................................................................................................4 WARNINGS AND PRECAUTIONS ......................................................................................4 ADVERSE REACTIONS .....................................................................................................15 DRUG INTERACTIONS......................................................................................................25 DOSAGE AND ADMINISTRATION ...................................................................................28 OVERDOSAGE ...................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY ...................................................................32 STORAGE AND STABILITY...............................................................................................36 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................36 PART II: SCIENTIFIC INFORMATION ..................................................................................37 PHARMACEUTICAL INFORMATION................................................................................37 CLINICAL TRIALS......................................................................... Lestu allt skjalið